NAUTILUS BIOTECHNOLOGY INC's ticker is NAUT and the CUSIP is 63909J108. A total of 82 filers reported holding NAUTILUS BIOTECHNOLOGY INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $46,534 | -17.9% | 14,726 | +0.5% | 0.00% | – |
| Q2 2023 | $56,680 | +43.4% | 14,646 | +2.6% | 0.00% | – |
| Q1 2023 | $39,522 | +33.5% | 14,268 | -13.3% | 0.00% | – |
| Q4 2022 | $29,608 | -10.3% | 16,449 | +4.5% | 0.00% | – |
| Q3 2022 | $33,000 | -17.5% | 15,740 | +4.6% | 0.00% | – |
| Q2 2022 | $40,000 | -28.6% | 15,049 | +16.9% | 0.00% | – |
| Q1 2022 | $56,000 | -38.5% | 12,877 | -26.4% | 0.00% | – |
| Q4 2021 | $91,000 | – | 17,485 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| AH Equity Partners Bio II, L.L.C. | 16,298,006 | $43,842,000 | 30.79% |
| Madrona Venture Group, LLC | 6,020,770 | $16,196,000 | 7.52% |
| AH Equity Partners LSV II, L.L.C. | 1,355,911 | $3,647,000 | 3.82% |
| Ally Bridge Group (NY) LLC | 1,080,566 | $2,907,000 | 2.65% |
| Tikvah Management LLC | 1,488,895 | $4,005,000 | 1.73% |
| ArchPoint Investors | 1,449,551 | $3,899,000 | 1.54% |
| Perceptive Advisors | 9,111,151 | $24,508,000 | 0.77% |
| Bain Capital Life Sciences Investors, LLC | 2,000,000 | $5,380,000 | 0.63% |
| CROWN ADVISORS MANAGEMENT, INC. | 250,000 | $672,000 | 0.62% |
| Affinity Asset Advisors, LLC | 466,607 | $1,255,000 | 0.53% |